Azetidine derivatives as CCR-3 receptor antagonists

Disclosed are compounds of formula I, wherein: Ar is phenyl optionally substituted by one or more substituents selected from halogen, alkyl, cyano or nitro; R1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, acyloxy, halogen, carboxy, alkoxycarbonyl, -N(R4)R5, -CON(R6)R7 or by a monovalent cyclic organic group having 3 to 15 atoms in the ring system; R2 is hydrogen, alkyl or cycloalkyl and R3 is alkyl substituted by phenyl, phenoxy, acyloxy or naphthyl, or R3 is cycloalkyl optionally having a benzo group fused thereto, a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms, phenyl or naphthyl, the phenyl, phenoxy or naphthyl groups being optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, acyl, nitro, -SO2NH2, alkyl optionally substituted by alkoxy, haloalkyl, alkoxy, haloalkoxy, alkylthio, -SO2-alkyl, alkoxycarbonyl, acylamino optionally substituted on the nitrogen atom by alkyl, alkylamino, aminocarbonyl, alkylamino-carbonyl, dialkylamino, dialkylaminocarbonyl, dialkylaminocarbonyl-methoxy, or alkylcarbonylamino, or R2 and R3 together with the nitrogen atom to which they are attached denote a heterocyclic group having 5 to 10 ring atoms of which 1,2 or 3 are hetero atoms; R4 and R5 are each independently hydrogen or alkyl, or R4 is hydrogen and R5 is hydroxy-alkyl, acyl, -SO2R8 or -CON(R6)R7 or R4 and R5 together with the nitrogen atom to which they are attached denote a 5-or 6-membered heterocyclic group; R6 and R7 are each independently hydrogen or alkyl, or R6 and R7 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group; R8 is alkyl, haloalkyl, or phenyl optionally substituted by alkyl, X is -C(=O)-, -O-, -CH2- or CH(OH); Y is oxygen or sulfur; m is 1, 2, 3 or 4; and n, p and q are each 0 or 1, n+p+q=1 or 2, n+q=1, p+q=1, and when n is 0, p is 0. The compounds are used in the manufacture of medicaments for the treatment of conditions mediated by CCR-3.